Wilmington, DE-based Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. The company conducts its European clinical development operations in Geneva, Switzerland.

The company’s hematology and oncology franchise is comprised of four approved products, which are Jakafi (ruxolitinib), Monjuvi (tafasitamab-cxix), Pemazyre (pemigatinib) and Iclusig (ponatinib), as well as numerous clinical development programs. Lead drug Jakafi is a first-in-class JAK1/JAK2 inhibitor, approved in the United States for the treatment of patients with polycythemia vera (“PV”), who have had an inadequate response to or are intolerant to hydroxyurea. It is also approved for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-PV MF, and post-essential thrombocythemia MF. The drug is also approved in the United States for treatment of steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients aged 12 years or older. While Incyte markets the drug in the United States, it is marketed by Novartis as Jakavi outside the country. Jakafi sales came in at $2.1 billion in 2021, contributing 77% to total revenues.

Opzelura, a novel cream formulation of ruxolitinib, was approved by the FDA in September 2021 for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD). The FDA also approved Tabrecta (capmatinib) for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC). Novartis has exclusive worldwide development and commercialization rights to Tabrecta, and Incyte will receive royalties on sales of the same.

Incyte also has a collaboration agreement with Eli Lilly for Olumiant (baricitinib). In June 2018, the FDA approved the 2mg dose of baricitinib as Olumiant for treating adults with rheumatoid arthritis (RA). The FDA recently approved Olumiant as a first-in-disease systemic treatment for adults with severe alopecia areata (AA), available as 4-mg, 2-mg and 1-mg tablets.